15.78

4.88% -0.81

Aurinia Pharmaceuticals Inc (AUPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AUPH Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$16.59

Aprire:

$16.49

Volume 24 ore:

1.20M

Relative Volume:

0.84

Capitalizzazione di mercato:

$2.03B

Reddito:

$298.30M

Utile/perdita netta:

$298.21M

Rapporto P/E:

7.2931

EPS:

2.1637

Flusso di cassa netto:

$166.93M

1 W Prestazione:

+1.09%

1M Prestazione:

+0.77%

6M Prestazione:

+4.16%

1 anno Prestazione:

+76.71%

Intervallo 1D:

$15.48

$16.54

Intervallo di 1 settimana:

$15.37

$16.70

Portata 52W:

$8.55

$19.25

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Nome

Aurinia Pharmaceuticals Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

250-744-2487

Indirizzo

#140, 14315 - 118 AVENUE, EDMONTON, BC

Dipendente

128

Cinguettio

@AuriniaPharma

Prossima data di guadagno

2026-07-30

Ultimi documenti SEC

AUPH's Discussions on Twitter

Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AUPH Aurinia Pharmaceuticals Inc	15.78	2.03B	298.30M	298.21M	166.93M	2.1637
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-03	Downgrade	Leerink Partners	Outperform → Market Perform
2025-11-07	Aggiornamento	Jefferies	Hold → Buy
2025-11-05	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-07-30	Ripresa	H.C. Wainwright	Buy
2022-11-04	Downgrade	Oppenheimer	Outperform → Perform
2022-05-05	Ripresa	Cantor Fitzgerald	Overweight
2021-12-10	Aggiornamento	Oppenheimer	Perform → Outperform
2021-10-28	Downgrade	Oppenheimer	Outperform → Perform
2021-01-25	Reiterato	H.C. Wainwright	Buy
2020-11-03	Reiterato	H.C. Wainwright	Buy
2020-06-17	Iniziato	BTIG Research	Buy
2020-05-05	Iniziato	Cowen	Outperform
2020-01-10	Iniziato	Jefferies	Buy
2019-12-16	Reiterato	H.C. Wainwright	Buy
2018-03-16	Reiterato	Cantor Fitzgerald	Overweight
2018-02-08	Iniziato	RBC Capital Mkts	Outperform
2017-10-30	Reiterato	H.C. Wainwright	Buy
2017-05-18	Reiterato	H.C. Wainwright	Buy
2017-04-11	Iniziato	Cantor Fitzgerald	Overweight
2017-03-22	Reiterato	FBR & Co.	Outperform
2016-12-30	Reiterato	H.C. Wainwright	Buy
2016-08-17	Reiterato	H.C. Wainwright	Buy
2016-06-30	Iniziato	H.C. Wainwright	Buy
2015-05-08	Iniziato	MLV & Co	Buy

Mostra tutto

Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie

Jul 11, 2026

Liquidity Mapping Around (AUPH) Price Events - Stock Traders Daily

Jul 11, 2026

Is Aurinia Pharmaceuticals (AUPH) Using Combination LN Trials to Redefine Its LUPKYNIS Strategy? - Sahm

Jul 11, 2026

Jul 09, 2026

Price to earnings forward of Aurinia Pharmaceuticals Inc. – MUN:IKAP - TradingView

Jul 09, 2026

Jul 07, 2026

AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView

Jul 07, 2026

Jul 06, 2026

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis - BioSpace

Jul 06, 2026

TD Cowen Maintains Aurinia Pharmaceuticals(AUPH.US) With Buy Rating, Maintains Target Price $17 - Moomoo

Jul 06, 2026

Aurinia Unchanged on Unveiling Lupus Treatment - Baystreet.ca

Jul 06, 2026

Aurinia launches trial combining lupus nephritis treatments - Investing.com

Jul 06, 2026

Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy - Moomoo

Jul 06, 2026

Aurinia launches trial combining lupus nephritis treatments By Investing.com - Investing.com South Africa

Jul 06, 2026

Jul 05, 2026

Aurinia Pharmaceuticals balances autoimmune drug focus and U.S. market ambitions - ad-hoc-news.de

Jul 05, 2026

Jul 04, 2026

Enterprise value to EBITDA forward of Aurinia Pharmaceuticals Inc – NASDAQ:AUPH - TradingView

Jul 04, 2026

Jul 03, 2026

If EPS Growth Is Important To You, Aurinia Pharmaceuticals (NASDAQ:AUPH) Presents An Opportunity - Moomoo

Jul 01, 2026

Jun 30, 2026

Why (AUPH) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Jun 30, 2026

Jun 29, 2026

Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now? - Insider Monkey

Jun 29, 2026

Jun 27, 2026

IKAP Forecast — Price Target — Prediction for 2027 - TradingView

Jun 27, 2026